Cell and Gene Therapy Services Comparison: Orsini vs PANTHERx vs Onco360 vs Accredo vs CVS
This comparison supports a manufacturer-side CGT launch decision: which specialty-pharmacy and access partner can handle product-specific requirements around cryogenic handling, REMS, treatment-center coordination, payer access, hub orchestration, and long-term follow-up.
Curated by Rx Almanac using company materials, public reporting, and editorial synthesis.
On this page
Save this comparison — email yourself the full breakdown.
Join 200+ biotech launch teams on the weekly digest.
Thesis
CGT service selection is not a generic specialty pharmacy RFP. The network has to connect product logistics, treatment-site readiness, payer authorization, patient navigation, and outcomes reporting without losing chain-of-identity or patient-level visibility.
Orsini Specialty Pharmacy is the most CGT-specialized independent in this comparison because it combines rare disease, hub, specialty pharmacy, and 3PL in one operating model. PANTHERx Rare is the rare-disease specialist extending aggressively into CGT via RxARECONCIERGE. Accredo and CVS Specialty bring payer and scale advantages, but with PBM-owned channel diligence. Onco360 matters most where the CGT-adjacent decision is oncology LDD design rather than cryogenic gene-therapy fulfillment.
Capability Matrix
| Capability | Orsini | PANTHERx Rare | Onco360 | Accredo / Evernorth | CVS Specialty |
|---|---|---|---|---|---|
| CGT operating center | Strongest independent CGT portfolio in the current source set; 12 CGTs documented | RxARECONCIERGE launched for CGT frontier | Oncology-specialized SP; not primarily CGT infrastructure | Therapy Link + Accredo clinical support + CuraScript SD adjacency | Dedicated specialty scale; oncology and rare disease centers of excellence |
| Cryogenic / ultra-cold logistics | Columbus SP + 3PL facility adds ultra-cold storage and redundancy | Public RxARECONCIERGE claims storage as low as -150 C | Not the core public proof point | Ultra-cold and complex shipping cited in Evernorth CGT materials | Must be validated product-by-product; scale is real but CGT specifics vary |
| REMS / LDD execution | Rare-disease and CGT LDD strength; integrated hub + SP + 3PL | Rare-disease REMS and LDD depth | Very strong oncology LDD launch cadence | Large TRC model and PBM/payer reach | Broadest LDD and payer footprint among SPs |
| Hub orchestration | Integrated hub capabilities inside Orsini model | Pharmacy-led support that complements manufacturer or third-party hubs | Oncology access, BV/PA, financial assistance | Accredo clinical + Evernorth payer / distribution assets | CVS Specialty / Caremark / Coram adjacency; channel conflicts require diligence |
| Payer access | Lower PBM leverage; stronger manufacturer alignment | Lower PBM leverage; independent rare-disease alignment | Conflict-free oncology positioning under BrightSpring | Strongest Evernorth / Express Scripts integration | Strongest CVS Caremark / Aetna / retail integration |
| Manufacturer data visibility | Strong fit when manufacturer wants continuity across hub, SP, and 3PL | Strong fit for rare-disease patient-level visibility | Strong oncology reporting and OncoMETRICS / OncoAdvocate signals | Must negotiate data rights and firewall terms | Must negotiate data rights, Caremark routing, and PBM-owned governance |
Competitive Intelligence
The first split is specialist independence versus PBM-owned scale. Orsini and PANTHERx are better suited when the product has ultra-rare patient populations, small treatment-center networks, high documentation burden, and manufacturer need for named-team continuity. Accredo and CVS are harder to avoid when payer access, broad formulary reach, or captive lives matter as much as disease intimacy.
The second split is CGT-specific logistics versus therapy-area depth. Orsini has the clearest integrated CGT + 3PL thesis. PANTHERx is building into CGT from a rare-disease operating base. Onco360 is not the default cryogenic CGT partner, but it is relevant for oncology products where limited distribution, financial assistance, BCOP support, and oncology practice workflows are the launch bottleneck.
The third split is who owns orchestration. Manufacturers can run a separate hub and treat the SP as a dispensing node, or they can select a pharmacy partner that absorbs more hub, logistics, and reporting work. The more autologous, REMS-heavy, or site-coordinated the therapy, the more costly handoffs become.
Launch Architecture Choices
CGT network design should be built around the product’s operational failure modes, not around a generic specialty pharmacy scorecard. The source set points to four architecture choices that determine vendor fit:
| Architecture choice | Specialist-independent posture | PBM-owned / scale posture |
|---|---|---|
| Patient identification and intake | Better fit when disease prevalence is low and every referral needs named-team handling. | Better fit when payer lives, claims signals, and broad network routing create the patient funnel. |
| Logistics and custody | Better fit when chain-of-identity, ultra-cold storage, 3PL redundancy, or treatment-center handoffs are core launch risks. | Better fit when standard specialty distribution plus broad payer pharmacy operations are sufficient. |
| Payer authorization | Often requires a manufacturer hub or separate PA partner to supplement the pharmacy. | Payer adjacency can improve routing visibility, but buyer must negotiate firewall and data-rights terms. |
| Long-term follow-up and reporting | Useful when manufacturer wants continuity from referral through outcomes registry. | Useful when the plan or PBM owns much of the post-fill data trail, but may reduce manufacturer transparency. |
Product-Fit Segmentation
The strongest CGT pharmacy partner for an autologous oncology therapy may not be the strongest partner for an ex vivo rare-disease therapy, an in vivo gene therapy, or an oncology product with CGT-like monitoring but ordinary cold-chain needs. Manufacturers should map the product to one of four segments before shortlisting vendors:
- Site-led autologous therapy: Treat treatment-center readiness, custody handoffs, courier coordination, and registry reporting as first-order requirements. The pharmacy may be less important than the integrated logistics / site-support model.
- Rare-disease gene therapy: Prioritize rare-disease patient navigation, benefits investigation, payer evidence packages, caregiver support, and high-touch adherence / follow-up.
- Oncology LDD with CGT-like monitoring: Use oncology clinical support and financial advocacy as the anchor, then add specialty logistics only where the product actually requires it.
- Broad specialty product with occasional CGT complexity: PBM-owned scale pharmacies may be unavoidable for access, but the manufacturer should carve out exceptions for complex sites, REMS, or ultra-cold handling.
Best For
- Orsini: CGT or ultra-rare launches needing integrated specialty pharmacy, hub, home-infusion or treatment-center support, and 3PL/cold-chain redundancy.
- PANTHERx Rare: Rare-disease CGT-adjacent launches where patient community intimacy, rare-disease accreditation, and high-touch support outrank PBM access.
- Onco360: Oncology LDD networks where BCOP support, oncology practice relationships, financial advocacy, and independent oncology focus are more important than cryogenic logistics.
- Accredo / Evernorth: Manufacturers that need payer connectivity, claims-data patient identification, field nursing, CuraScript SD adjacency, and broad Evernorth scale.
- CVS Specialty: Broad specialty or oncology launches where CVS Caremark, Aetna, retail pickup, Coram adjacency, and large national specialty operations are commercially necessary.
Key Diligence Questions
- Which temperature band is required for storage, pack-out, and shipment, and which facilities are validated for that exact band?
- Who owns chain-of-identity, chain-of-custody, and treatment-center handoff documentation?
- Is the partner operating a true CGT program or adapting a general specialty workflow?
- Which REMS tasks, prescriber certifications, patient enrollments, and lab-monitoring steps are in scope?
- How does the vendor coordinate pharmacy-benefit PA, medical-benefit PA, buy-and-bill, and treatment-site authorization?
- What patient-level data will be delivered to the manufacturer, at what cadence, and with what PBM / payer firewall terms?
- How will long-term follow-up, registry support, adverse-event routing, and outcomes reporting work after first administration?
- What is the backup plan if the preferred site, courier, freezer, payer route, or pharmacy node fails?
Implications
CGT launches should separate the “pharmacy” decision from the “orchestration” decision. Orsini and PANTHERx may be stronger where manufacturer visibility, rare-disease continuity, and logistics specialization matter most, while Accredo and CVS can be necessary where payer access and national scale determine whether patients can start therapy. Onco360 belongs in oncology-adjacent networks where the product behaves like an oral oncology LDD rather than a cryogenic cell therapy (see Cell & Gene Therapy Commercialization, REMS & Limited Distribution Drug Networks, and the vendor profiles cited in Sources).
The buyer implication is to write the RFP around failure modes. Test chain-of-identity, site scheduling, payer authorization, backup logistics, adverse-event routing, and long-term follow-up as integrated scenarios. A partner that can dispense but cannot coordinate treatment-site readiness or registry data may be adequate for conventional specialty but under-specified for CGT.
Related Links
- Orsini Specialty Pharmacy
- PANTHERx Rare
- Onco360 Oncology Pharmacy
- Accredo / Evernorth
- CVS Specialty Pharmacy
- Specialty Pharmacy Competitive Landscape
- PBM-Owned vs Independent Specialty Pharmacy Competitive Analysis
- Cell & Gene Therapy Commercialization
- REMS & Limited Distribution Drug Networks
Rx Almanac maintains a private source register for each article. Material public claims are cited inline; sourcing standards and correction policy are described in our methodology.
Related Articles
Analysis
340B TPA Comparison: Apexus vs Sentry Data Systems vs Macro Helix
Covered-entity 340B TPA comparison for Apexus, Sentry Data Systems, and Macro Helix, with manufacturer channel-risk implications.
Analysis
Oncology Pharmacy Network Design: LDD Segmentation and Specialty Pharmacy Selection
This analysis gives manufacturer launch teams a practical oncology specialty pharmacy network design framework: when to use Onco360, when to include PBM-owned SPs, when health-system pharmacies matter, and when independent specialists or rare-disease pharmacies should be in the network.
Analysis
Big Three PBM Specialty Pharmacy Operations
The Big Three PBM specialty pharmacies are not simply large dispensing vendors; they are vertically integrated control points that combine formulary leverage, network steering, specialty fulfillment, copay/maximizer economics, and private-label biosimilar strategy.
Get more analysis like this
Weekly pharma vendor intel: new comparisons, market updates, and expert insights.
Found an inaccuracy? Tell us.
Suggest a correction